<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Ang Chan, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew Kulke, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas E Clancy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H90693957"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neuroendocrine cells are distributed widely throughout the body, and neuroendocrine neoplasms of these dispersed cells can arise at many sites. The classification and nomenclature of neuroendocrine neoplasms arising within the digestive system has evolved over the past two decades (see  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Classification and terminology'</a>):</p><p>Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies characterized by variable biologic behavior. Clinical behavior and prognosis correlate closely with histologic differentiation and grade, as assessed by mitotic count and/or Ki-67 labeling index  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Classification and terminology'</a>.)</p><p>Systemic treatment approaches to control tumor growth and symptoms related to hormone hypersecretion for patients with advanced or metastatic well-differentiated NET arising in the pancreas will be reviewed here. Systemic therapy options for patients with advanced or metastatic well-differentiated gastrointestinal tract NET (carcinoid) are discussed elsewhere, as are the clinical presentation, imaging, biochemical monitoring, pathology, and classification of gastroenteropancreatic NET; localization and treatment of pancreatic NET; evaluation and management of NET of unknown primary site; management of symptoms of functioning pancreatic NET; local management options to control tumor growth and symptoms of hormone excess for well-differentiated metastatic gastroenteropancreatic NET; and the evaluation and management of patients with high-grade gastroenteropancreatic neuroendocrine carcinoma.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p></p><p class="headingAnchor" id="H90693963"><span class="h1">CLASSIFICATION AND BIOLOGIC BEHAVIOR</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) classifies all gastroenteropancreatic NENs into low-grade (G1), intermediate-grade (G2), and high-grade (G3) categories based on mitotic count and proliferative index (Ki-67)  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Poorly differentiated neuroendocrine carcinomas (NEC) are high grade by definition. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on '2010 and 2019 World Health Organization classification'</a>.)</p><p>As a group, well-differentiated gastroenteropancreatic NETs are generally indolent malignancies with a prolonged natural history. However, clinical behavior is heterogeneous, as evidenced by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>NETs arising in the tubular gastrointestinal tract and pancreas may have similar characteristics on routine histologic evaluation, but they have a different pathogenesis and biology [<a href="#rid2">2</a>]. Pancreatic NETs in general pursue a somewhat more aggressive course than do other gastrointestinal tract NETs [<a href="#rid3">3</a>], although, conversely, most systemic agents have been associated with higher response rates among patients with pancreatic NETs than in those with gastrointestinal NET. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>G2 gastroenteropancreatic NETs have a slightly worse prognosis than do G1 NETs [<a href="#rid4">4</a>]. Although they are classified and treated similarly at present, as new treatment modalities become available, it is likely that the histologic grade of a well-differentiated NET will affect the selection of appropriate treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, poorly differentiated neuroendocrine carcinomas have a rapidly progressive clinical course and a poor prognosis. They are generally treated with platinum-based chemotherapy regimens. (See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a small subset of well-differentiated tumors with a proliferative rate that places them in the high-grade category (G3 NETs). These tumors have a clinical behavior that is midway between G2 NETs and neuroendocrine carcinomas. Management is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'High-grade, well-differentiated tumors (NET G3)'</a>.)</p><p></p><p class="headingAnchor" id="H90693969"><span class="h1">GENERAL APPROACH TO THE PATIENT</span><span class="headingEndMark"> — </span>The majority of patients with advanced pancreatic NETs have liver metastases [<a href="#rid5">5</a>]. Most tumors (between 50 and 75 percent) are nonfunctioning and are not associated with a hormonal syndrome. (See  <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms", section on 'Clinical presentation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms of hormone secretion</strong> – Patients with symptoms of hormone hypersecretion from a well-differentiated pancreatic NET should be managed with somatostatin analogs and other agents as appropriate to the specific syndrome. In general, initial therapy for insulinomas consists of carbohydrates and <a class="drug drug_general" data-topicid="9346" href="/z/d/drug information/9346.html" rel="external">diazoxide</a>, which directly inhibits the release of insulin from insulinoma cells. Careful monitoring is necessary in insulinoma patients when initiating therapy with somatostatin analogs, which may paradoxically worsen hypoglycemia due to decreased secretion of counterregulatory hormones. <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> can also be highly effective in improving glycemic control in patients with insulinoma. For patients with gastrinoma, high doses of oral proton pump inhibitors are the treatment of choice. Somatostatin analogs may be helpful for refractory cases. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potentially resectable disease</strong> – For patients who have potentially resectable metastatic disease, resection may provide prolonged control of symptoms and tumor growth. Although the majority of patients recur, even if resection is complete, metastasectomy is generally preferred over medical therapy for patients with potentially resectable liver metastases. (See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Surgical resection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unresectable</strong> <strong>disease</strong> – Somatostatin analogs and the molecularly targeted agents <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> and <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> have been shown to improve progression-free survival (PFS) duration relative to supportive care alone in patients with metastases from a nonfunctioning pancreatic NET. For patients with low-volume disease who are asymptomatic, we suggest waiting until disease progression or development of symptoms related to tumor bulk before beginning systemic therapy. For most patients with a metastatic pancreatic NET who are felt to require therapy, we suggest somatostatin analogs rather than a molecularly targeted agent as initial therapy because of the more favorable side effect profile. (See <a class="local">'Benefits'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapy at progression</strong> – If an initial approach of observation is chosen, initiation of a somatostatin analog should be considered at the time of progression.</p><p></p><p class="bulletIndent1">For patients with radiologic disease progression despite use of a somatostatin analog at standard doses, therapeutic options for those with hepatic-predominant disease include noncurative surgical debulking and nonsurgical liver-directed therapy (eg, transarterial bland embolization, chemoembolization, or radioembolization). (See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Hepatic-predominant metastatic disease'</a> and  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Surgical resection'</a> and  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Nonsurgical liver-directed therapy'</a>.)</p><p></p><p class="bulletIndent1">For patients with more widespread disease that is not eligible for liver-directed therapy, systemic therapy options include <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, cytotoxic chemotherapy, peptide receptor radioligand therapy (PRRT; eg, lutetium-177 [<sup>177</sup>Lu] dotatate, for somatostatin receptor-expressing tumors), or dose-escalated somatostatin analog therapy. Studies evaluating the optimal sequencing of therapy have not been conducted. Furthermore, interpretation of an attempted network meta-analysis to rank the relative efficacy and toxicity of a variety of systemic therapies for NETs is limited due to variability in patient populations, variability in eligibility and response criteria, a lack of trials directly comparing active treatments, as well as unclear efficacy of the comparator arm in some cases (such as interferon) [<a href="#rid6">6,7</a>]. (See <a class="local">'Molecularly targeted therapy'</a> below and <a class="local">'Cytotoxic chemotherapy'</a> below and <a class="local">'Peptide receptor radioligand therapy'</a> below.)</p><p></p><p class="bulletIndent1">A single randomized trial directly comparing PRRT with <sup>177</sup>Lu dotatate versus <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02230176%3Fterm%3D02230176%26rank%3D1&amp;token=Ste%2FJ%2B0Zk8%2BGCpKsBOssVXs7REdxnziGg6IyMw%2BTV0KDbRivO5wpXLhD8Vgeu4G0O2sZuiAIDy%2BINHzzpiYmKenTnHX6us1AzXarMr%2FZ8OQ%3D&amp;TOPIC_ID=90664" target="_blank">NCT02230176</a>) for progressive disease in 84 patients with no prior cytotoxic therapy, previous PRRT or TKI inhibitor therapy concluded that median PFS was significantly better with <sup>177</sup>Lu dotatate [<a href="#rid8">8</a>]. This trial is discussed in more detail below. (See <a class="local">'Efficacy versus other treatments'</a> below.)</p><p></p><p class="bulletIndent1">For most patients, we prefer participation in a clinical trial. Otherwise, there is no clear consensus on the appropriate sequencing of available therapies. If trial participation is not available or desired, the following represents our approach to treatment:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are highly symptomatic from tumor bulk or who have rapidly enlarging metastases, we suggest chemotherapy rather than molecularly targeted therapy or PRRT. For most patients, we suggest the combination of <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> (CAPTEM) rather than temozolomide alone. In the absence of comparative trials, the choice of CAPTEM over a streptozocin-containing regimen should be individualized, taking into account the convenience of oral rather than intravenous treatment, performance status, and the anticipated side effect profile of both combinations. (See <a class="local">'Dacarbazine and temozolomide-based regimens'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with progressing somatostatin receptor-expressing tumors who are not highly symptomatic from tumor bulk and who do not have rapidly enlarging metastases, we suggest <sup>177</sup>Lu dotatate rather than molecularly targeted therapy or chemotherapy. (See <a class="local">'Lutetium-177 dotatate'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The molecularly targeted agents <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> and <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> improve PFS duration relative to supportive care alone in patients with metastases from a nonfunctioning pancreatic NET. These drugs represent an appropriate alternative to <sup>177</sup>Lu dotatate for patients whose disease has progressed while receiving a somatostatin analog who do not have highly symptomatic disease or rapidly enlarging metastases, especially if not all tumors express somatostatin receptors. The choice of agent is often based on the expected side effect profile, which differs between these two agents. (See <a class="local">'Sunitinib'</a> below and <a class="local">'Everolimus'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another option for patients with indolent disease after an initial response or a prolonged duration of stability with standard-dose somatostatin analog therapy is dose escalation of the somatostatin analog. (See <a class="local">'Control of tumor growth'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The benefit of continuing therapy with a standard-dose long-acting somatostatin analog in patients whose disease has progressed while receiving such therapy, and who are initiating other medical forms of therapy, is not well defined. For patients with nonfunctional tumors who experience unequivocal radiographic progression on a somatostatin analog and for whom a switch in therapy is planned, we would discontinue the somatostatin analog. For patients with functional tumors, we continue the somatostatin analog to minimize the effects of hormone secretion.</p><p></p><p>The following sections will discuss systemic treatment options to control symptoms related to tumor bulk, or hormone hypersecretion and tumor growth for well-differentiated pancreatic NETs. Local treatment options for gastroenteropancreatic NETs, including resection and liver-directed therapy (such as embolization), are discussed in detail elsewhere, as are systemic therapy for well-differentiated gastrointestinal tract NETs and treatment approaches for high-grade gastroenteropancreatic neuroendocrine carcinomas. (See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a> and  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a> and  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p class="headingAnchor" id="H90693975"><span class="h1">SOMATOSTATIN ANALOGS</span><span class="headingEndMark"> — </span>Somatostatin is a 14-amino acid peptide that inhibits the secretion of a broad range of hormones in vivo. Somatostatin and analogs of somatostatin (such as <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> and <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">lanreotide</a>) act by binding to somatostatin receptors (SSTRs), which are expressed on the majority of NETs [<a href="#rid9">9</a>]. The ability of octreotide and lanreotide to inhibit the secretion of peptides from NET cells is mediated mainly through SSTR-2 and SSTR-5.</p><p>The presence of SSTRs can be determined by diagnostic imaging using a radiolabeled somatostatin analog. Options include SSTR-PET CT or SSTR-PET MRI, with appropriate SSTR-PET tracers including <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> (Ga-68 DOTATATE), gallium Ga-68 DOTATOC (Ga-68 DOTATOC), or <a class="drug drug_general" data-topicid="129471" href="/z/d/drug information/129471.html" rel="external">copper Cu-64 DOTATATE</a> (Cu-64 DOTATATE). <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">Octreotide</a> SPECT/CT with Indium-111 [111-In] pentetreotide [OctreoScan] is an option if SSTR-PET CT is not available. The higher sensitivity of SSTR-PET makes this a preferred imaging modality, particularly in certain clinical situations such as patients with smaller tumor volume. In general, uptake of radiotracer by the tumor is predictive of a response to therapy with somatostatin analogs. However, in some cases (eg, miliary disease), diagnostic imaging may be negative even if SSTRs are present on the tumor. In such cases, a trial of somatostatin analog therapy can be considered even in the presence of a negative scan. (See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p class="headingAnchor" id="H1108125295"><span class="h2">Benefits</span></p><p class="headingAnchor" id="H601802518"><span class="h3">Patients with symptoms from hormone secretion</span><span class="headingEndMark"> — </span>Patients with metastases from functioning pancreatic NETs (which account for 10 to 30 percent of all pancreatic NETs [<a href="#rid10">10</a>]) often become symptomatic from hormone hypersecretion rather than from tumor bulk. For those who have octreotide-avid disease, symptoms of hormonal excess can often be well controlled with somatostatin analogs.</p><p>In series that include patients with only pancreatic NETs or combined series of patients with functioning gastroenteropancreatic NETs (gastrointestinal NETs and pancreatic NETs), somatostatin analogs provide symptom control in over 60 percent [<a href="#rid11">11-19</a>]. However, symptomatic benefit is dose-related, and also differs according to the type of functioning NET:</p><p class="bulletIndent1"><span class="glyph">●</span>Somatostatin analogs are highly effective in controlling the symptoms associated with VIPomas (watery diarrhea) and glucagonomas (especially improvement in the characteristic rash, necrolytic migratory erythema) [<a href="#rid20">20,21</a>]. (See  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Efficacy has also been shown for somatostatinomas [<a href="#rid22">22,23</a>], although the effects are may be less dramatic than with VIPomas and glucagonomas. (See  <a class="medical medical_review" href="/z/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management", section on 'Somatostatin analogue'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insulinomas and gastrinomas represent the most common types of functioning pancreatic NET, but the role of somatostatin analogs in controlling hormone-related symptoms is somewhat limited:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Efficacy of somatostatin analogs for insulinomas with hypoglycemia is unpredictable [<a href="#rid24">24-29</a>], and somatostatin analogs should be used with caution in this setting. Only approximately one-half of these tumors express SSTRs and derive benefit from such therapy. Furthermore, somatostatin analogs may paradoxically result in transient worsening of hypoglycemia, presumably due to simultaneous inhibition of glucagon secretion. In general, initial therapy for insulinomas often consists of dietary modification. Treatment with <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> may improve glycemic control in patients with insulinoma. Treatment with <a class="drug drug_general" data-topicid="9346" href="/z/d/drug information/9346.html" rel="external">diazoxide</a>, which directly inhibits the release of insulin from insulinoma cells, is another option. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma", section on 'Medical therapy to control symptomatic hypoglycemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The role of somatostatin analogs in patients with hormone-related symptoms from gastrinoma is also limited. High doses of oral proton pump inhibitors are the treatment of choice, as they are able to effectively control the hypergastrinemia-related gastric acid overproduction. Somatostatin analogs may be helpful in refractory cases. (See  <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a>.)</p><p></p><p>Currently available somatostatin analogs include <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> and <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">lanreotide</a>. Highly symptomatic patients may be initiated on short-acting octreotide with rapid transition to a long-acting formulation and subsequent titration of dose to optimize symptom control while the LAR formulation is starting to take effect. However, a depot preparation (Sandostatin LAR) has largely eliminated the need for daily octreotide injections and is now considered a standard approach for symptomatic treatment of advanced NETs [<a href="#rid30">30,31</a>]. Many clinicians initiate therapy with the depot preparation for most patients and do not give an initial dose of short-acting octreotide. Sandostatin LAR is typically initiated at a dose of 20 mg IM monthly with gradual dose escalation as needed for optimal symptom control [<a href="#rid32">32</a>]. Patients may use additional short-acting octreotide for breakthrough symptoms while doses are being titrated; therapeutic levels of octreotide are not reached until 10 to 14 days after the initiation of the LAR injection.</p><p><a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">Lanreotide</a>, another long-acting somatostatin analog, can be administered once monthly using a deep subcutaneous injection and appears to have similar efficacy to <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid15">15-17</a>].</p><p class="headingAnchor" id="H90693987"><span class="h3">Control of tumor growth</span><span class="headingEndMark"> — </span>In addition to controlling symptoms associated with hormone hypersecretion, somatostatin analogs have also been shown to control tumor growth. Given the variable and sometimes indolent disease course of some pancreatic NETs, the optimal time to initiate treatment with a somatostatin analog in asymptomatic patients remains uncertain. We suggest initiation of a somatostatin analog in patients with unresectable, asymptomatic, well-differentiated pancreatic NET and a high tumor burden, an approach that is consistent with guidelines from the European Neuroendocrine Tumor Society (ENETS) [<a href="#rid31">31</a>], North American Neuroendocrine Society (NANETS) [<a href="#rid33">33</a>], and the National Comprehensive Cancer Network (NCCN) [<a href="#rid34">34</a>]. For patients with asymptomatic, advanced, unresectable pancreatic NET and small-volume disease, we suggest initial observation alone rather than early administration of a somatostatin analog. In such patients, we initiate somatostatin analog therapy if there is evidence of clinically meaningful tumor progression.</p><p>Past studies have indicated that few patients with advanced gastroenteropancreatic NET (&lt;10 percent) have objective tumor shrinkage with somatostatin analogs [<a href="#rid31">31,35-38</a>], even when limited to subgroups with progressive disease at the time of treatment initiation [<a href="#rid12">12-14,35,39-41</a>]. However, more reports have demonstrated that, in addition to an improvement in symptoms, treatment with somatostatin analogs may be associated with disease stabilization and significant prolongation of progression-free survival (PFS) [<a href="#rid42">42-44</a>]. Whether somatostatin analogs also increase overall survival is not yet known, although a correlation between PFS and overall survival in patients with advanced NET treated with single-agent somatostatin analog therapy has been shown [<a href="#rid45">45</a>].</p><p>Median duration of PFS and overall survival depends on several factors, including primary tumor location, Ki-67 percent, extent of liver metastases, presence of bone and/or peritoneal metastases, and the presence of symptoms when initiating treatment. A nomogram has been developed to estimate PFS in patients with well-differentiated gastroenteropancreatic NETs based upon these and other factors [<a href="#rid46">46</a>].</p><p>The PROMID study, which was the first randomized study demonstrating an antiproliferative effect of somatostatin analogs in NET, included patients with metastatic small intestinal NET who were treated with <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> LAR versus placebo [<a href="#rid42">42</a>]. Because the study was limited to patients with small intestinal NET, applicability of these results to patients with pancreatic NET was uncertain. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p>However, support for the antiproliferative effect of somatostatin analogs in pancreatic NET was provided by the phase III CLARINET trial, which compared <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">lanreotide</a> versus placebo in 204 patients with advanced well- or moderately differentiated, nonfunctioning gastroenteropancreatic NET, including both gastrointestinal NET and pancreatic NET (45 percent of all enrollees) [<a href="#rid43">43</a>]. Patients were randomly assigned to receive either 120 mg lanreotide Autogel (n = 101) or placebo (n = 103) every four weeks for 96 weeks or until progressive disease (PD) or death. The trial’s primary end point was PFS as determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria  (<a class="graphic graphic_table graphicRef74693" href="/z/d/graphic/74693.html" rel="external">table 2</a>). All patients had avid disease on somatostatin-receptor scintigraphy. Most patients (96 percent) had no tumor progression by RECIST criteria in the three to six months before randomization; approximately one-half had pancreatic primary sites. Compared with placebo, there was a highly significant advantage in PFS with the use of lanreotide. At a time-point of two years following initiation of treatment, median PFS was not reached with lanreotide compared with 18 months with placebo (hazard ratio [HR] for progression or death 0.47; 95% CI 0.30-0.73). Estimated rates of 24-month PFS were 65 versus 33 percent. There were no significant differences in quality of life or overall survival. The most common treatment-related adverse effect was diarrhea (26 versus 9 percent in the lanreotide and placebo groups, respectively). Based upon these data, lanreotide has been approved in the United States for the treatment of patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic NET.</p><p>The mechanisms by which somatostatin analogs control tumor growth may result from direct antiproliferative effects, including cell cycle inhibition and pro-apoptotic effects, and indirect antiproliferative effects, including inhibition of tumor angiogenesis and the release of trophic growth hormones [<a href="#rid47">47</a>]. <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">Octreotide</a> LAR and <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">lanreotide</a> are first-generation agents that primarily target SSTR-2 and SSTR-5; benefit for the addition of the second-generation somatostatin analog <a class="drug drug_general" data-topicid="87457" href="/z/d/drug information/87457.html" rel="external">pasireotide</a>, which targets multiple SSTR subtypes, with greater binding affinity for SSTR-1, SSTR-3, and SSTR-5,<sub> </sub>and lower affinity for SSTR-2, could not be shown in a randomized phase II trial of <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> with or without pasireotide [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H2779970216"><span class="h4">Dose-escalated therapy</span><span class="headingEndMark"> — </span>Dose escalation is an option at the time of initial disease progression on a long-acting somatostatin analog, but it is not our preferred option. The benefits of escalating the dose and/or frequency of a somatostatin analog for disease control are not well established, and clinical practice is variable. At least some data suggest the potential for prolonged periods of stable disease when the dose intensity is increased (eg, by using higher than standard doses or reducing the dosing interval) after an initial period of long-acting somatostatin analog use [<a href="#rid49">49,50</a>]. However, whether this reflects indolent biology rather than an intrinsic dose-response relationship is not clear. Furthermore, how this strategy compares with other systemic treatments for disease control after progression on a long-acting somatostatin analog (eg, peptide receptor radioligand therapy) is not known. (See <a class="local">'Peptide receptor radioligand therapy'</a> below.)</p><p class="headingAnchor" id="H1739139482"><span class="h4">Choice of lanreotide versus octreotide LAR</span><span class="headingEndMark"> — </span>The choice of <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> LAR versus <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">lanreotide</a> should be based on patient preference. Although both drugs are equally acceptable and efficacious treatments for well-differentiated NETs, they differ substantially in cost [<a href="#rid51">51</a>]. While it was originally hypothesized that a deep subcutaneous injection of lanreotide might be less painful compared with intramuscular injection of octreotide LAR, a randomized trial specifically designed to assess patient experience and drug preference in 51 patients initiating therapy with a long-acting SSA concluded that there was minimal pain with either drug and no significant pain score difference between the two [<a href="#rid52">52</a>]. Of the 34 patients who indicated a drug preference, more than half had no preference, and among those who did, there was a trend toward favoring octreotide LAR, but the numbers were very small.</p><p class="headingAnchor" id="H1108124125"><span class="h2">Side effects</span><span class="headingEndMark"> — </span>Somatostatin analogs are usually well tolerated, and side effects are generally mild [<a href="#rid53">53,54</a>]. Approximately one-third of patients may have mild nausea, abdominal discomfort, bloating, loose stools, and fat malabsorption during the first weeks of therapy, after which time, symptoms tend to subside. Use of pancreatic enzyme supplements can ameliorate symptoms associated with pancreatic insufficiency. Mild glucose intolerance may occur due to transient inhibition of insulin secretion. Somatostatin analogs reduce postprandial gallbladder contractility and delay gallbladder emptying; up to 25 percent of patients develop asymptomatic gallstones or sludge within the first 18 months of therapy [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H199296649"><span class="h1">CYTOTOXIC CHEMOTHERAPY</span><span class="headingEndMark"> — </span>Well-differentiated pancreatic NETs are clearly responsive to cytotoxic chemotherapy  (<a class="graphic graphic_table graphicRef63537" href="/z/d/graphic/63537.html" rel="external">table 3</a>). For patients who are highly symptomatic from tumor bulk or who have rapidly enlarging metastases, we suggest chemotherapy rather than molecularly targeted therapy or a somatostatin analog because of the higher objective response rate. For most patients, we suggest the combination of <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> (CAPTEM) rather than temozolomide alone. In the absence of comparative trials, the choice of CAPTEM over a streptozocin-containing regimen should be individualized, taking into account the convenience of oral rather than intravenous treatment, performance status, and the anticipated side effect profile of both combinations.</p><p class="headingAnchor" id="H199296699"><span class="h2">Dacarbazine and temozolomide-based regimens</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">Dacarbazine</a> is an alkylating agent (like <a class="drug drug_general" data-topicid="9949" href="/z/d/drug information/9949.html" rel="external">streptozocin</a>), with activity against pancreatic NET. In an Eastern Cooperative Oncology Group (ECOG) phase II trial of dacarbazine in 42 patients with advanced pancreatic islet cell carcinomas, the objective response rate was 33 percent [<a href="#rid55">55</a>]. As with streptozocin, the toxicity of dacarbazine-based regimens has limited their widespread use.</p><p><a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> is a less toxic orally active analog of <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> with activity in pancreatic NET [<a href="#rid56">56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CAPTEM</strong> – Accumulating data support promising activity with <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> (CAPTEM) in patients with pancreatic NET  (<a class="graphic graphic_table graphicRef63537" href="/z/d/graphic/63537.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective series of 143 patients who were treated with CAPTEM, the response rate was 54 percent [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Benefit of CAPTEM relative to <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> alone was shown in the phase II ECOG-American College of Radiology Imaging Network (ACRIN) study 2211, which randomly assigned 144 patients with unresectable or metastatic pancreatic NET (low-grade [n = 76] or intermediate-grade [n = 57]) and progressive disease within the past 12 months to temozolomide alone (200 mg/m<sup>2</sup> daily on days 1 through 5 every 28 days) or <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> (750 mg/m<sup>2</sup> twice daily on days 1 through 14) plus temozolomide (200 mg/m<sup>2</sup> orally daily on days 10 through 14), also given in 28-day cycles [<a href="#rid58">58</a>]. On-protocol treatment was prespecified as 13 cycles, after which time patients could receive any treatment at investigator discretion.</p><p></p><p class="bulletIndent2">At the first interim analysis, conducted in 2018, median progression-free survival (PFS), the primary endpoint, was significantly better with combined therapy(median follow-up 29 months, 22.7 versus 14.4 months, hazard ratio 0.58, 95% CI 0.36-0.93). In the final analysis, which was conducted in May 2021, there was a trend toward better median overall survival (58.7 versus 53.8 months, HR 0.82, 95% CI 0.51-1.33) with combined therapy, which was also associated with a higher objective response rates (40 versus 34 percent, p = 0.42), higher overall disease control rate (objective response plus stable disease; 84 versus 74 percent), and longer duration of response (16.6 versus 12.6 months). Of note, there was an imbalance in tumor grade between the treatment arms, with less grade 2 disease in the CAPTEM arm. Treatment-related grade 3 or 4 adverse effects were twice as common with combined therapy (44 versus 22 percent); the most common were neutropenia (13 versus 4 percent), nausea and vomiting (8 versus 0 percent), diarrhea (8 versus 0 percent), and fatigue (8 versus 1 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong><a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a><strong> combinations</strong> – In prospective studies, temozolomide has been combined with other agents, including <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, with overall response rates of 24 to 45 percent  (<a class="graphic graphic_table graphicRef63537" href="/z/d/graphic/63537.html" rel="external">table 3</a>) [<a href="#rid59">59-61</a>]. In these studies, temozolomide has generally been administered using a dose-intense regimen of 150 mg/m<sup>2</sup> daily for seven days on an every-other-week schedule. Prophylaxis for <em>Pneumocystis</em> <em>jirovecii</em> pneumonia is recommended in light of the lymphopenia associated with long-term use of temozolomide according to this schedule. The relative contribution of temozolomide and the agent used in combination with it to the observed antitumor activity is unclear.</p><p></p><p class="headingAnchor" id="H199296737"><span class="h3">Role of MGMT expression</span><span class="headingEndMark"> — </span>As has been noted in patients with glioblastoma, there appears to be a correlation between expression of methylguanine DNA methyltransferase (MGMT) and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> responsiveness in advanced NET. MGMT is an enzyme that is responsible for DNA repair induced by alkylating agent chemotherapy. Cells with a lower amount of MGMT may be more sensitive to alkylating agents such as temozolomide. (See  <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">"Initial treatment and prognosis of IDH-wildtype glioblastoma in adults", section on 'MGMT methylation status'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, of 21 patients treated with temozolomide-based regimens, none of the 16 with intact MGMT expression (including all 13 carcinoid tumors) responded to treatment, while four of the five patients whose tumors lacked MGMT expression (all with pancreatic NET) had a radiologic response [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second larger retrospective series also reported an association between MGMT status and response to alkylating agents (including <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a>, and streptozotocin-based regimens) in patients with NET [<a href="#rid63">63</a>]. In this study, the association between MGMT status and response to alkylating agents was observed in patients with either gastrointestinal or pancreatic NET.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional data are now available from the phase II ECOG/ACRIN study 2211 [<a href="#rid58">58</a>], described above. (See <a class="local">'Dacarbazine and temozolomide-based regimens'</a> above.)</p><p></p><p class="bulletIndent1">While the study was not designed to test MGMT as a predictive marker for response to <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, MGMT deficiency (as detected by loss of immunohistochemical [IHC] protein expression or promoter methylation) was associated with a greater odds of response to treatment. As an example, the response rate to treatment with CAPTEM or temozolomide was 52 percent (33/63) in patients whose tumors had low MGMT expression, compared to 15 percent in patients whose tumors had a high MGMT expression (5/34). Similarly, among 50 patients treated with CAPTEM, the response rate was 57 percent in patients whose tumors had low MGMT expression (21/37), compared with 8 percent in those with high MGMT expression (1/13).</p><p></p><p class="bulletIndent1">Of note, only seven of 57 cases tested had <em>MGMT</em> promoter methylation, while low expression by IHC was seen in 63 of 97 cases tested (including all cases with promoter methylation), suggesting that mechanisms other than promoter methylation are involved in MGMT downregulation in NETs. Interestingly, at least some data suggest that fluoropyrimidines such as <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> might synergize with <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, perhaps by downregulating O6-methylguanine-DNA methyltransferase (<em>MGMT</em>) gene expression [<a href="#rid64">64</a>].</p><p></p><p>Confirmatory testing is needed to assess whether MGMT is a predictive biomarker of response to temozolomide-based therapy. In addition, variability in the techniques and criteria used to assess MGMT status preclude its current use as a routine clinical test to select patients for treatment with <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, with or without <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Dacarbazine and temozolomide'</a>.)</p><p class="headingAnchor" id="H3874012647"><span class="h2">Streptozocin combinations</span><span class="headingEndMark"> — </span>Streptozocin-based combination therapy has been a historical treatment standard for patients with advanced pancreatic NET  (<a class="graphic graphic_table graphicRef63537" href="/z/d/graphic/63537.html" rel="external">table 3</a>). Antitumor efficacy can be illustrated by the following data:</p><p class="bulletIndent1"><span class="glyph">●</span>In an early randomized trial, <a class="drug drug_general" data-topicid="9949" href="/z/d/drug information/9949.html" rel="external">streptozocin</a> plus <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> had a combined biochemical and radiologic response rate of 69 percent and a median survival of 2.2 years [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective analysis of 84 patients with either locally advanced or metastatic pancreatic NET treated with <a class="drug drug_general" data-topicid="9949" href="/z/d/drug information/9949.html" rel="external">streptozocin</a>, <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU), and <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> and using current standard response criteria reported a 39 percent objective radiographic response rate and a median survival duration of 37 months [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another retrospective analysis of 96 patients with pancreatic NETs treated with <a class="drug drug_general" data-topicid="9949" href="/z/d/drug information/9949.html" rel="external">streptozocin</a> plus FU reported an objective response rate of 43 percent, and an additional 41 percent had stable disease as the best response [<a href="#rid67">67</a>].</p><p></p><p>While streptozocin-based regimens are clearly active in patients with advanced pancreatic NETs, widespread use has been limited by a relatively cumbersome administration schedule and by concerns about toxicity, which can include myelosuppression, nausea, hair loss, and renal dysfunction [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H199296743"><span class="h2">Oxaliplatin-containing regimens</span><span class="headingEndMark"> — </span>Reports suggest antitumor activity for some oxaliplatin-based regimens in pancreatic NET [<a href="#rid69">69,70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A combined analysis of two phase II trials examining oxaliplatin-fluoropyrimidine chemotherapy plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in advanced NET suggests antitumor activity for these regimens. The analysis included a study examining the efficacy of <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> plus short term infusional FU and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (FOLFOX) with bevacizumab (n = 36) and another examining <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> in combination with oxaliplatin and bevacizumab (n = 40) [<a href="#rid69">69</a>]. The best overall responses based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria in 12 patients with pancreatic NET treated with FOLFOX-bevacizumab included 50 percent with a partial response and 50 percent with stable disease. The outcomes in 16 patients with pancreatic NET treated with capecitabine with oxaliplatin and bevacizumab were 18.8 percent with a partial response and 69 percent with stable disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The contribution of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> to these results is unclear; similar benefit has been shown with <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> alone [<a href="#rid70">70</a>].</p><p></p><p class="headingAnchor" id="H90694077"><span class="h1">MOLECULARLY TARGETED THERAPY</span><span class="headingEndMark"> — </span>For patients with advanced pancreatic NETs whose disease has progressed on a somatostatin analog and who are not symptomatic from tumor bulk that would benefit from cytoreduction, we suggest treatment with a molecularly targeted agent (<a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> or <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>).</p><p>Progress in the understanding of the molecular biology of pancreatic NETs has revealed elevated expression of several cellular growth factors and their receptors (including vascular endothelial growth factor [VEGF] and the VEGF receptor [VEGFR]), and involvement of the mammalian Target of Rapamycin (mTOR) in pancreatic neuroendocrine tumorigenesis [<a href="#rid71">71-73</a>]. Many receptors like VEGFR function as tyrosine kinases (TKs). The finding in preclinical models that disruption of VEGFR signaling pathways inhibits neuroendocrine cell growth has prompted a number of clinical trials evaluating small molecule TK inhibitors (eg, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, and <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>) and monoclonal antibodies (MoAbs) that target VEGF in patients with advanced NET.</p><p>Studies have demonstrated antitumor activity associated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> (an anti-VEGF MoAb), and several TK inhibitors that inhibit VEGFR, as well as the mTOR inhibitor <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. As has been seen with cytotoxic chemotherapy, these agents appear to be more active in pancreatic NET than in advanced gastrointestinal NET (carcinoid). (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Molecularly targeted therapy'</a>.)</p><p class="headingAnchor" id="H90694089"><span class="h2">Small molecule antiangiogenic TK inhibitors</span></p><p class="headingAnchor" id="H90694095"><span class="h3">Sunitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">Sunitinib</a> is a multi-targeted tyrosine kinase (TK) inhibitor that has shown activity against a range of signaling pathways and growth factors/receptors including VEGFR 1, 2, and 3 as well as PDGFR alpha and beta, KIT, glial cell-line derived neurotrophic factor, RET, FMS-like tyrosine kinase-3 (FLT3), and colony-stimulating factor receptor (CSF-1R).</p><p>In an initial phase II trial, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (50 mg daily for four of every six weeks) was administered to 109 patients with advanced NET [<a href="#rid74">74</a>]. Of 61 patients with pancreatic NET, 11 (18 percent) had a partial response, and 68 percent had prolonged periods of stable disease; median time to tumor progression (TTP) was 7.7 months. Rates of symptom control for patients with functioning tumors and refractory symptoms were not reported.</p><p>Continuous administration of <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (37.5 mg daily) was compared with placebo in a phase III trial of 171 patients with progressing pancreatic NET [<a href="#rid75">75</a>]. Accrual was stopped prematurely prior to the first preplanned interim efficacy analysis. Median progression-free survival (PFS) was significantly longer with sunitinib (11.4 versus 5.5 months). There were eight objective responses with sunitinib (versus none in the placebo group), two of which were complete. Hand-foot skin reaction and hypertension of any grade occurred in 23 and 26 percent of patients receiving sunitinib, respectively, and the most common grade 3 or 4 adverse events in this group were neutropenia (12 percent) and hypertension (10 percent). Despite these side effects, there were no differences in the quality-of-life index with sunitinib. Rates of symptom control for patients with functioning tumors and refractory symptoms were not reported. In a later report, median overall survival favored sunitinib (38.6 versus 29.1 months), but the difference was not statistically significant, potentially due to crossover from placebo to sunitinib in 69 percent of the control group [<a href="#rid76">76</a>].</p><p>Largely based upon these data, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> was approved in the United States for the treatment of progressive, well-differentiated pancreatic NET in patients with unresectable, locally advanced, or metastatic disease. Side effects may include hypertension, proteinuria, and other forms of renal toxicity, arterial thromboembolism, left ventricular dysfunction, and clinical heart failure, thyroid dysfunction, bleeding, myelosuppression, hand-foot skin reaction, delayed wound healing, hepatotoxicity, and muscle wasting. These side effects and their management are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy", section on 'VEGFR/PDGFR inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p>Although few data are available, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> provided control of refractory symptoms due to tumor hormone production in two patients with VIPomas [<a href="#rid77">77</a>]. By contrast, blood glucose concentrations were not increased in a single patient treated with sunitinib for a functioning metastatic insulinoma [<a href="#rid78">78</a>]. Furthermore, worsening hypoglycemia in patients with insulinoma and development of hypoglycemia in patients with a previously nonfunctioning pancreatic NET related to hyperinsulinemia have been reported [<a href="#rid78">78-80</a>].</p><p class="headingAnchor" id="H90694101"><span class="h3">Sorafenib and pazopanib</span><span class="headingEndMark"> — </span>Two other orally active antiangiogenic TK inhibitors, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> and <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, have demonstrated modest activity in pancreatic NET in phase II studies:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">Sorafenib</a>, which targets VEGFR-2 and PDGFR-beta, was evaluated in 43 patients with pancreatic NET [<a href="#rid81">81</a>]. In a preliminary analysis, responses were observed in 9 percent of the 41 evaluable patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">Pazopanib</a>, which targets VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha and beta, as well as KIT, was evaluated in a prospective study of 51 patients with advanced NET (29 with pancreatic NET and 22 with carcinoid) on stable doses of octreotide-LAR [<a href="#rid82">82</a>]. Patients received pazopanib at a dose of 800 mg daily. The response rate among patients with well-differentiated pancreatic NET was 22 percent.</p><p></p><p class="headingAnchor" id="H3993419050"><span class="h3">Cabozantinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">Cabozantinib</a>, which targets VEGFRs, MET, AXL, and RET, was evaluated in a prospective study of 61 patients with advanced NETs (20 pancreatic and 41 gastrointestinal NETs). Patients started at a dose of 60 mg of cabozantinib daily. In a preliminary report, the response rate was 15 percent for patients with pancreatic NETs, with an encouraging median PFS of 21.8 months [<a href="#rid83">83</a>]. The CABINET trial, a randomized placebo-controlled phase III study, is currently enrolling patients and will evaluate the efficacy of cabozantinib in patients with advanced pancreatic and gastrointestinal NETs after prior therapy with <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03375320%3Fterm%3D03375320%26rank%3D1&amp;token=Ste%2FJ%2B0Zk8%2BGCpKsBOssVXs7REdxnziGg6IyMw%2BTV0KDbRivO5wpXLhD8Vgeu4G0m%2BTJHS3ohwZmQcd7nWvD2ZhKN915tFAe%2FJUbCd01rlg%3D&amp;TOPIC_ID=90664" target="_blank">NCT03375320</a>).</p><p class="headingAnchor" id="H3564497415"><span class="h3">Lenvatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">Lenvatinib</a>, which targets VEGFRs as well as fibroblast growth factor (FGF) receptors, was studied in the phase II TALENT trial of 111 patients with advanced NETs (55 pancreatic and 56 gastrointestinal) [<a href="#rid84">84</a>]. All of the pancreatic NET patients had progressed after being treated with a targeted agent (<a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> in 69 percent, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> in 29 percent). The objective response rate was 44 percent for the pancreatic NETs, and the median duration of response was 19.9 months (range 8.4 to 30.8).</p><p class="headingAnchor" id="H1631286902"><span class="h3">Surufatinib</span><span class="headingEndMark"> — </span>The SANET-p trial, a randomized, double-blind, placebo-controlled phase III trial conducted in China that included 172 patients with progressive advanced pancreatic NET, demonstrated improvement in PFS with surufatinib versus placebo [<a href="#rid85">85</a>]. Investigator-assessed median PFS was 10.9 months in the surufatinib group versus 3.7 months in the placebo group (HR 0.49, 95% CI 0.32–0.76; p = 0.0011). Overall survival data was not mature at the time of the interim analysis; survival follow-up is ongoing. Surufatinib is not currently available or FDA approved in the United States [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H90694107"><span class="h2">mTOR inhibitors</span></p><p class="headingAnchor" id="H90694113"><span class="h3">Everolimus</span><span class="headingEndMark"> — </span>Several nonrandomized studies have explored the activity of <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, with and without <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid87">87-89</a>]. The activity of everolimus (10 mg daily) in pancreatic NET was initially explored in an international multicenter phase II trial of 160 patients, 45 of whom also received treatment with concurrent octreotide at the discretion of the investigators [<a href="#rid87">87</a>]. Median PFS was longer in patients who received octreotide plus everolimus compared with everolimus alone (17 versus 9.7 months), but whether the addition of octreotide contributed to the higher PFS is unclear since the study did not randomly assign patients to receive octreotide.</p><p><a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> monotherapy (10 mg daily) was compared with best supportive care alone in the placebo-controlled RADIANT-3 trial of 410 patients with advanced progressing pancreatic NET [<a href="#rid90">90</a>]. Everolimus was associated with a significant prolongation in median PFS (11 versus 4.6 months, hazard ratio [HR] for progression 0.35, 95% CI 0.27 to 0.45). There were confirmed objective partial responses (as defined by Response Evaluation Criteria in Solid Tumors [RECIST] v1.0  (<a class="graphic graphic_table graphicRef74693" href="/z/d/graphic/74693.html" rel="external">table 2</a>)) in 5 percent of patients receiving everolimus versus 2 percent of the placebo group. Drug-related adverse events were mostly grade 1 or 2, and included stomatitis (64 versus 17 percent of the placebo group), rash (49 versus 10 percent), diarrhea (34 versus 10 percent), fatigue (31 versus 14 percent), and infections (23 versus 6 percent), predominantly of the upper respiratory tract. The most common grade 3 or 4 drug-related adverse events were stomatitis (7 percent), anemia (6 percent), and hyperglycemia (5 percent). In a later analysis, median survival favored everolimus (44 versus 37.7 months), but the difference was not statistically significant [<a href="#rid91">91</a>]. The high rate of crossover of patients from placebo to everolimus (85 percent) may have confounded the ability to detect a difference in overall survival.</p><p>Largely based upon these data, <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> was approved in the United States for the treatment of progressive NET of pancreatic origin in patients with unresectable, locally advanced, or metastatic disease.</p><p><a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> causes hyperglycemia, particularly in those with preexisting hyperglycemia. In analysis of data from the RADIANT-3 trial described above, the frequency of severe (grade 3 or 4) hyperglycemia was higher in those with preexisting diabetes mellitus or baseline hyperglycemia (15 versus 3 percent in those without diabetes or baseline hyperglycemia) [<a href="#rid92">92</a>]. Interestingly, rates of grade 3 or 4 hyperglycemia were similar in those with glucagonoma versus those without glucagonoma (9.1 versus 7.8 percent). (See  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'Laboratory abnormalities'</a>.)</p><p>Largely because of this effect, <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> may be of particular value in patients with functioning insulinomas and refractory hypoglycemia [<a href="#rid93">93-96</a>]. In one report, four patients with malignant insulinoma and refractory hypoglycemia normalized their glucose levels during everolimus therapy; two had an objective antitumor response [<a href="#rid93">93</a>]. Clinical improvement in the other two patients who had stable disease as the best response suggests a possible direct effect of the drug on insulin production and/or release. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a>.)</p><p>Though rare, <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> has been associated with serious, adverse events, including pneumonitis [<a href="#rid96">96</a>]; tolerance should be carefully monitored during therapy. (See  <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Everolimus'</a>.)</p><p class="headingAnchor" id="H322929995"><span class="h4">Everolimus plus bevacizumab</span><span class="headingEndMark"> — </span>Both VEGF pathway and mTOR inhibitors are active in pancreatic NET. The benefit of adding <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> to <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> was addressed in a phase II trial in which 150 patients with locally advanced or metastatic pancreatic NET were randomly assigned to everolimus alone (10 mg by mouth daily) or with concurrent bevacizumab (10 mg/kg IV every two weeks) [<a href="#rid97">97</a>]. Combination therapy was associated with significantly higher response rate (31 versus 12 percent) and superior PFS (16.7 versus 14 months), but no overall survival benefit. Combined therapy was also associated with higher rates of serious grade 3 or higher toxicity, including diarrhea (14 versus 3 percent), hyponatremia (11 versus 3 percent), and hypertension (41 versus 12 percent). Although the higher rate of treatment-related adverse events may limit the use of this combination, the results support the continued evaluation of VEGF pathway inhibitors in pancreatic NET.</p><p class="headingAnchor" id="H90694119"><span class="h3">Temsirolimus</span><span class="headingEndMark"> — </span>In a phase II study of 37 patients with progressive NET treated with the mTOR inhibitor <a class="drug drug_general" data-topicid="10344" href="/z/d/drug information/10344.html" rel="external">temsirolimus</a>, only 1 of 15 patients with pancreatic NET had an objective response, but 67 percent attained disease control (which included stable disease for at least two months) [<a href="#rid98">98</a>]. Higher baseline tumor levels of mTOR predicted for better outcomes.</p><p>Encouraging early results were noted in a phase II trial of <a class="drug drug_general" data-topicid="10344" href="/z/d/drug information/10344.html" rel="external">temsirolimus</a> (25 mg IV weekly) plus the anti-VEGF monoclonal antibody <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> (10 mg/kg every other week) in 56 patients with RECIST criteria progression within seven months of study entry [<a href="#rid99">99</a>]. A confirmed partial response was documented in 23 patients (41 percent), and 44 (79 percent) remained progression free at six months. The most common grade 3 or 4 toxic effects related to therapy were hypertension (21 percent), hyperglycemia (14 percent), fatigue (16 percent), neutropenia, and headache (7 percent each).</p><p class="headingAnchor" id="H1232350929"><span class="h1">PEPTIDE RECEPTOR RADIOLIGAND THERAPY</span></p><p class="headingAnchor" id="H1322155235"><span class="h2">Radiolabeled somatostatin analogs</span><span class="headingEndMark"> — </span>For patients without rapidly progressive pancreatic NET that expresses somatostatin receptors (SSTRs), we suggest peptide receptor radioligand therapy (PRRT) using a radiolabeled somatostatin analog such as lutetium-177 (<sup>177</sup>Lu) dotatate, rather than molecularly targeted therapy or chemotherapy. However, the optimal sequencing of this agent with regard to other therapies is debated, and there is no consensus on this issue [<a href="#rid100">100</a>].</p><p>Traditional external beam radiotherapy is beneficial for patients with painful bone metastases but has little utility for the more common visceral metastases. There has been substantial interest, however, in targeted radiotherapy using systemic administration of radiolabeled somatostatin analogs [<a href="#rid101">101-111</a>]. The most frequently used radionuclides for targeted radiotherapy are yttrium-90 (<sup>90</sup>Y) and lutetium-177 (<sup>177</sup>Lu), which differ from one another in terms of emitted particles, particle energy, and tissue penetration [<a href="#rid112">112-114</a>].</p><p>Transarterial radioembolization (TARE) using <sup>90</sup>Y-radiolabeled glass or starch microspheres is a different procedure that is a local ablative treatment administered via the hepatic artery. Use of TARE to treat advanced NETs is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Technique and outcomes'</a>.)</p><p>Most of the series reporting efficacy and toxicity with systemic administration of radiolabeled somatostatin analogs have included both pancreatic NET and gastrointestinal NET [<a href="#rid112">112,113,115,116</a>]. The following data will focus on pancreatic primary NETs, where possible.</p><p class="headingAnchor" id="H1763411450"><span class="h3">Yttrium-90 dotatoc</span><span class="headingEndMark"> — </span>The most extensive experience with <sup>90</sup>Y dotatoc comes from a large single-institution series of 1109 patients with metastatic gastroenteropancreatic NET (primary in the pancreas in 342) and disease progression within 12 months of study entry, with visible tumor uptake on pretreatment SSTR scintigraphy [<a href="#rid115">115</a>]. After the initial dose, additional treatment cycles were withheld if there was tumor progression or permanent toxicity; otherwise, patients were offered retreatment. The specific interval was not specified. The median number of courses administered was two (range 1 to 10).</p><p>Overall, 378 patients (34 percent) had a "morphologic" response (defined as any measurable decrease in the sum of the longest diameters of all pre-therapeutically detected tumor lesions by computed tomography [CT], magnetic resonance imaging [MRI], or ultrasound), 172 (15 percent) had a biochemical response (defined as any post-treatment decrease in a tumor marker that had demonstrated progression prior to enrollment), and 329 (29.7 percent) improved symptomatically. In the subset of patients with pNET, there was great variability in the range of morphologic (20 to 75 percent), biochemical (zero to 40 percent), and clinical responses (zero to 60 percent), depending on tumor subtype and whether the tumor was functional or nonfunctional. Among the 295 nonfunctioning pNETs, the morphologic, biochemical, and clinical response rates were 49, 14, and 29 percent, respectively.</p><p>The median survival from diagnosis was 94.6 months. Longer survival correlated with responses by any of the above criteria. Transient grade 3 or 4 hematologic toxicities developed in 142 (12 percent), and loss of renal function was the main dose-limiting toxicity. In all, 103 patients (9 percent) had permanent grade 4 or 5 (fatal, n = 35) renal toxicity. Older age, low baseline glomerular filtration rate, and high kidney uptake score were associated with severe nephrotoxicity.</p><p class="headingAnchor" id="H3119698645"><span class="h3">Lutetium-177 dotatate</span><span class="headingEndMark"> — </span>At least some data suggest that <sup>177</sup>Lu dotatate outperforms <sup>90</sup>Y dotatoc [<a href="#rid114">114</a>]. In a registry-based series of 450 patients with pancreatic or gastrointestinal NET, 54 percent were treated with <sup>177</sup>Lu dotatate alone, 17 percent were treated with <sup>90</sup>Y dotatoc alone, and combined therapy was administered to 29 percent [<a href="#rid114">114</a>]. The median progression-free survival (PFS) for the entire group was 41 months (27 months with <sup>90</sup>Y dotatoc alone, 40 months for <sup>177</sup>Lu dotatate, and 50 months for combined therapy). The nonrandomized nature of this series precludes drawing conclusions regarding the relative efficacy of these approaches; however, long-term side effects of peptide receptor radioligand therapy (PRRT) may include loss of renal function, pancytopenia, and myelodysplastic syndrome, although rates of severe (grade 3 or worse) toxicity are reported to be low (1 percent or less) [<a href="#rid114">114</a>].</p><p>Efficacy results with <sup>177</sup>Lu dotatate alone are available from the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>In one series of 443 Dutch patients with gastroenteropancreatic or lung NET, the objective response rate was 39 percent, and an additional 43 percent had stable disease [<a href="#rid117">117</a>]. At a median follow-up of 78 months, median PFS was 29 months, median time to tumor progression was 36 months, and median overall survival was 63 months. Response rates were particularly high in pancreatic NET, ranging from 52 percent for nonfunctioning tumors to 62 percent for functioning gastrinomas, insulinomas, and VIPomas.</p><p></p><p class="bulletIndent1">The safety analysis included 610 patients who had received a cumulative dose of at least 100 millicuries (3.7 gigabecquerels). Acute treatment-related toxicity included grade 3 or 4 thrombocytopenia in 5 percent, lymphopenia in 50 percent, and elevated aminotransferases in 3 percent. Long-term toxicity included acute leukemia in four patients (0.7 percent, three fatal) and myelodysplastic syndrome in nine (1.5 percent, five fatal). There was no therapy-related long-term renal or hepatic failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 15 studies in combined populations of gastrointestinal and pancreatic NETs, totaling 872 patients with metastatic disease, the pooled objective response rate following a course of <sup>177</sup>Lu dotatate was 28 percent (95% CI 21-35 percent), and the pooled disease control rate was 79 percent (95% CI 76-82 percent) [<a href="#rid118">118</a>]. Early adverse effects were minimal, including nausea, vomiting, fatigue, and hormonal disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to these data, among patients with advanced midgut NET, the benefits of <sup>177</sup>Lu dotatate were shown in the NETTER-1 trial, which demonstrated significant improvement in objective response rate, PFS, and overall survival with <sup>177</sup>Lu dotatate compared with high-dose long-acting <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> in patients whose disease had progressed on standard-dose somatostatin analog therapy (median PFS not reached versus 18 months) [<a href="#rid116">116</a>]. All patients enrolled in this trial had an extrapancreatic primary site; these data are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Radiolabeled somatostatin analogs'</a>.)</p><p></p><p>Largely based on data from the NETTER-1 trial, in January 2018, the US Food and Drug Administration (FDA) approved <sup>177</sup>Lu dotatate for the treatment of somatostatin-receptor-positive gastroenteropancreatic NET, including those arising in the pancreas [<a href="#rid119">119</a>]. The recommended dose is 7.4 gigabecquerels (200 millicuries) as an intravenous infusion over 30 minutes every eight weeks for a total of four doses [<a href="#rid120">120</a>].</p><p>The optimal selection of candidates for <sup>177</sup>Lu dotatate is not established. Guidelines from the European Neuroendocrine Tumor Society, which largely mirror the eligibility criteria for the NETTER-1 trial, are outlined in the table  (<a class="graphic graphic_table graphicRef116972" href="/z/d/graphic/116972.html" rel="external">table 4</a>) [<a href="#rid121">121</a>]. We agree with these guidelines.</p><p>The limitations of <sup>177</sup>Lu dotatate at present include the complexity of administration, the lack of trials comparing this agent with other systemic therapies, and the limited widespread availability.</p><p class="headingAnchor" id="H18975326"><span class="h4">Efficacy versus other treatments</span><span class="headingEndMark"> — </span>There are few data comparing <sup>177</sup>Lu dotatate versus other therapies for progressive disease.</p><p class="bulletIndent1">A single randomized trial directly compared PRRT with <sup>177</sup>Lu dotatate versus <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> for progressive disease in 84 patients with no prior cytotoxic therapy, previous PRRT or TKI inhibitor therapy [<a href="#rid8">8</a>]. Notably, 81 percent of patients had grade 2 or 3 tumors, and 37 percent had Ki-67 levels &gt;10 percent. In a preliminary report presented at the 2022 ESMO cancer congress, at a median follow-up of 40 months, the primary end point, (PFS at 12 months) was twofold higher with <sup>177</sup>Lu dotatate (81 versus 42 percent) and median PFS was also double that in the sunitinib arm (20.7 versus 11 months). Grade 3 or 4 events were reported less commonly with <sup>177</sup>Lu dotatate (44 versus 63 percent).</p><p></p><p>In our view, while there remains no clear consensus on optimal sequencing of therapy, the higher rates of anti-tumor activity and better tolerability observed with <sup>177</sup>Lu dotatate in patients with advanced somatostatin receptor-expressing pNET makes this a preferable initial to molecularly targeted therapy for appropriate patients, particularly those who are symptomatic from their disease.</p><p>Additional randomized trials comparing different systemic therapy approaches are needed to define the optimal sequence of available therapies, including chemotherapy, and eligible patients should be encouraged to enroll in available trials, such as the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A European phase III trial, SEQTOR, is comparing the efficacy and safety of chemotherapy (<a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> and streptozotocin) followed by <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> versus everolimus followed by fluorouracil and streptozotocin in patients with advanced and progressive pancreatic NETs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The phase III COMPETE trial is evaluating PRRT with <sup>177</sup>Lu-edotreotide versus <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, the randomized phase II Alliance A022001 trial is evaluating PRRT with <sup>177</sup>Lu dotatate versus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> in patients with advanced pancreatic NETs (NCT05247905).</p><p></p><p class="headingAnchor" id="H2351833812"><span class="h4">Long-term toxicity</span><span class="headingEndMark"> — </span>The most serious long-term toxicity associated with PRRT is irreversible myelotoxicity and therapy-related myeloid neoplasms, including myelodysplastic syndrome, acute leukemia, myeloproliferative neoplasms, or any type of myeloid neoplasm. The available data from studies with long-term follow-up suggest a rate of myelodysplastic syndrome of approximately 2 percent and a rate of acute leukemia of approximately 0.5 percent.</p><p>Rates may be higher in those who received concurrent chemotherapy [<a href="#rid122">122</a>]. As an example, in a long-term Australian study of 104 patients followed for a period of 68 months after enrolling on two clinical trials of <sup>177</sup>Lu dotatate with either concurrent <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> or capecitabine plus <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, at a median follow-up of 68 months, seven patients (6.7 percent) developed MDS/acute leukemia, with a median time to onset of 5 years (range two to seven years) after PRRT. All but one case occurred after four years. Administering PRRT with concurrent chemotherapy is not recommended outside of a clinical trial.</p><p>Given the risk and the poor prognosis after a diagnosis of therapy-related myeloid neoplasms, clinicians should closely monitor patients with periodic complete blood counts (CBC) after PRRT [<a href="#rid123">123</a>]. We suggest obtaining a CBC with differential at least every six months, and prompt referral to a hematologist if abnormalities are detected. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Risks'</a>.)</p><p class="headingAnchor" id="H4164105246"><span class="h4">Should the somatostatin analog be continued?</span><span class="headingEndMark"> — </span>The added benefit of combining a long-acting somatostatin analog with PRRT compared with PRRT alone is not established. All patients in the NETTER-1 trial continued receiving the long-acting somatostatin analog during and after PRRT. At least some data from a retrospective analysis of 168 patients treated at a single institution for unresectable gastroenteropancreatic NETs suggest that combined therapy is associated with significantly better median PFS (48 versus 27 months) and overall survival (91 versus 47 months) [<a href="#rid124">124</a>] compared with PRRT alone.</p><p>For patients with a functional NET, we continue therapy with a somatostatin analog during and after PRRT. For patients with a nonfunctional NET, we typically continue therapy with the somatostatin analog, although we consider stopping it for a patient with a nonfunctional NET whose disease is progressing unequivocally on somatostatin analog therapy. This approach is consistent with guidelines from the European Society for Medical Oncology [<a href="#rid125">125</a>].</p><p class="headingAnchor" id="H672761563"><span class="h2">Iobenguane I-131</span><span class="headingEndMark"> — </span>Benefit also has been suggested for systemic radionuclide therapy using iodine-131-labeled iobenguane (iobenguane I-131) in individuals with metastatic gastroenteropancreatic NET whose tumors express the norepinephrine transporter and take up iobenguane, as determined by scintigraphy using radiolabeled iobenguane [<a href="#rid126">126</a>]. There are different iobenguane nuclides used for therapeutic and diagnostic purposes. <a class="drug drug_general" data-topicid="118601" href="/z/d/drug information/118601.html" rel="external">Iobenguane I-131 (therapeutic)</a> is also known as metaiodobenzylguanidine (MIBG or <sup>131</sup>I-MIBG); iobenguane expression is demonstrated by uptake on <a class="drug drug_general" data-topicid="9084" href="/z/d/drug information/9084.html" rel="external">iobenguane I-123 (diagnostic)</a> scintigraphy. While iobenguane I-131 has been licensed by regulatory authorities in some countries and is approved in the United States for treatment of pheochromocytoma/paraganglioma and neuroblastoma, in our view, its use for the treatment of gastroenteropancreatic NET remains investigational.</p><p>Iobenguane is a compound resembling norepinephrine that is accumulated by some NETs. In retrospective series, biochemical responses were observed in 37 percent of patients with gastroenteropancreatic NET treated with iobenguane I-131, objective radiographic responses were noted in 28 percent, and symptomatic improvement was reported by 27 of 48 patients (56 percent) [<a href="#rid127">127</a>].</p><p>In another report, <a class="drug drug_general" data-topicid="118601" href="/z/d/drug information/118601.html" rel="external">iobenguane I-131 (therapeutic)</a> was "beneficial" in 73 percent of 20 patients with metastatic gastroenteropancreatic NETs (including eight with pancreatic NETs) [<a href="#rid128">128</a>]. Treatment was judged beneficial if clinical status improved, laboratory tests for secreting tumors improved by &gt;20 percent, tumor progression was halted, the size of the most significant localization had decreased by &gt;25 percent, and the dose of analgesic and cold somatostatin analog therapy could be lowered. Treatment was well tolerated, and only one patient had severe pancytopenia. Notably, at 12 months, 7 of the 14 responders were again symptomatic.</p><p class="headingAnchor" id="H2732339566"><span class="h1">IMMUNOTHERAPY</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitors appear to have little activity as monotherapy, and they are not indicated, unless in the context of a clinical trial. Early data suggest promise for combinations of immunotherapy with other immune modulating agents; however, future studies are needed to better define the role of such treatment strategies for well-differentiated NET.</p><p>The role of immunotherapy with immune checkpoint inhibitors has been evaluated in several studies including patients with well-differentiated NETs. Data suggest that anti-programmed cell death 1 (PD-1) antibodies have minimal activity as monotherapy [<a href="#rid129">129</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of the anti-PD-1 antibody spartalizumab (PDR001) was evaluated in a phase II multicenter trial that enrolled 116 patients, including 33 with pancreatic NETs, 32 with gastrointestinal NETs, 30 with thoracic NETs, and 21 with poorly differentiated gastroenteropancreatic neuroendocrine carcinomas [<a href="#rid130">130</a>]. In a preliminary report presented at The 2018 European Society for Medical Oncology (ESMO) meeting, the clinical activity of spartalizumab was notable in patients with thoracic NETs (partial response rate 20 percent) but appeared marginal in other cohorts, including well-differentiated pancreatic NETs (partial response rate 3 percent, stable disease rate 55 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activity of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> in patients with programmed cell death 1 ligand (PD-L1)-positive advanced NET was evaluated in the KEYNOTE-028 study, which enrolled 16 patients with pancreatic NETs and 25 patients with gastrointestinal (n = 7), lung (n = 9), or other site (n = 9) NETs. Only one patient with a pancreatic NET had an objective response (6 percent); the stable disease rate in the 14 patients who were evaluable for response was 88 percent [<a href="#rid131">131</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The relevance of PD-L1 expression as a predictive factor for response was called into question by the phase II KEYNOTE-158 trial, which included a cohort of 107 patients with well- and moderately differentiated NET whose disease had progressed or who were intolerant of one or more lines of standard therapy [<a href="#rid132">132</a>]. PD-L1 expression was present in 16 percent of patients. Primary sites of disease included the pancreas (n = 40), small intestine (n = 25), other gastrointestinal sites (n = 18), lung (n = 14), and other organs (n = 10). There were only four partial responses (3.7 percent), and the median progression-free survival (PFS) was 4.1 months. Partial responses were noted in three patients with pancreatic NET and in one with an unknown primary; all responding tumors were PD-L1 negative. Two of the responding patients had a sustained response approaching two years.</p><p></p><p>Trials are ongoing to evaluate checkpoint inhibitors in combination with other immunomodulatory agents, including vascular endothelial growth factor (VEGF) pathway inhibitors [<a href="#rid133">133-135</a>]. As an example, a phase II trial evaluated the combination of the anti-PD-1 antibody <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in patients with well-differentiated G1 to G2 pancreatic and extrapancreatic (ep) NET [<a href="#rid133">133</a>]. Objective response was observed in 4 of 20 patients with pNETs (20 percent) and 3/20 patients with epNETs (15 percent). The PFS was 14.9 (95% CI 4.4-32.0) months and 14.2 (95% CI 10.2-19.6) months in these two cohorts, respectively.</p><p class="headingAnchor" id="H2144539315"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H90694174"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and categorization</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuroendocrine precursor cells are distributed widely throughout the body, and neoplasms of these dispersed cells, which are termed neuroendocrine neoplasms (NENs), can arise at many sites.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The World Health Organization (WHO) classifies all gastroenteropancreatic NENs based on differentiation and grade. Grade is assigned into low-grade neuroendocrine tumors (NETs), intermediate-grade NETs, and high-grade neoplasms based on mitotic count and proliferative index (Ki-67)  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>). Poorly differentiated neuroendocrine carcinomas are all high-grade by definition. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on '2010 and 2019 World Health Organization classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients with symptoms of hormone hypersecretion from a pancreatic NET (pNET) other than insulinoma or gastrinoma should be managed with somatostatin analogs and other agents, as appropriate to the specific syndrome. (See <a class="local">'Benefits'</a> above and  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Somatostatin analogs'</a> and  <a class="medical medical_review" href="/z/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'General measures'</a>.)</p><p></p><p class="bulletIndent2">Because somatostatin analogs may worsen glycemic control in insulinoma, initial therapy for insulinomas ore often consists of dietary modifications, <a class="drug drug_general" data-topicid="9346" href="/z/d/drug information/9346.html" rel="external">diazoxide</a>, which directly inhibits the release of insulin from insulinoma cells, and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, which improves glycemic control in patients with insulinoma. Specific recommendations are provided separately. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma", section on 'Medical therapy to control symptomatic hypoglycemia'</a>.)</p><p></p><p class="bulletIndent2">For patients with gastrinoma, most of whom have peptic ulcer disease, high doses of oral proton pump inhibitors are the initial treatment of choice; somatostatin analogs are may be helpful for refractory cases. Specific recommendations are provided separately. (See  <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with unresectable, asymptomatic, well-differentiated pNET and a high tumor burden, we suggest initiation of a long-acting somatostatin analog rather than observation (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For asymptomatic patients with low-volume disease, we suggest observation alone rather than early administration of a somatostatin analog (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In such patients, we initiate somatostatin analog therapy at the time of clinically meaningful disease progression. (See <a class="local">'Control of tumor growth'</a> above.)</p><p></p><p class="bulletIndent2">For most patients with hepatic metastases that are resectable with curative intent, in the absence of extrahepatic metastases, diffuse bilobar involvement, or compromised liver function, resection is generally preferred rather than medical therapy. Specific recommendations are provided separately. (See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Surgical resection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive disease and/or symptomatic from tumor bulk</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who require therapy because of progressive disease or symptoms related to hormone production, and who are not already receiving treatment with a somatostatin analog, we suggest a long-acting somatostatin analog rather than a different form of medical therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> may be of particular value in patients with functioning insulinomas and refractory hypoglycemia because of its association with hyperglycemia. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma", section on 'Medical therapy to control symptomatic hypoglycemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who are already receiving treatment with a somatostatin analog, options include cytotoxic chemotherapy, a molecularly targeted agent (<a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> or <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>), hepatic artery embolization for hepatic-predominant disease, or, for somatostatin receptor-expressing tumors, <sup>177</sup>Lu Dotatate.</p><p></p><p class="bulletIndent2">For patients who are highly symptomatic from tumor bulk and who have rapidly enlarging metastases, we suggest chemotherapy as an initial treatment because of the higher objective response rate compared with other approaches (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For most patients, we suggest the combination of <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> (CAPTEM) rather than temozolomide alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In the absence of comparative trials, the choice of CAPTEM over a streptozocin-containing regimen should be individualized, taking into account the convenience of oral rather than intravenous treatment, performance status, and anticipated side effect profiles. (See <a class="local">'Streptozocin combinations'</a> above and <a class="local">'Dacarbazine and temozolomide-based regimens'</a> above.)</p><p></p><p class="bulletIndent2">Hepatic arterial embolization is a reasonable alternative approach to systemic therapy for patients with hepatic predominant, but unresectable disease, particularly those who are symptomatic. Specific recommendations are provided separately. (See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Hepatic arterial embolization'</a>.)</p><p></p><p class="bulletIndent2">While there remains no clear consensus on optimal sequencing of therapy, the higher rates of anti-tumor activity observed with <sup>177</sup>Lu dotatate and CAPTEM in patients with advanced pNET make them preferred initial options rather than molecularly targeted therapy for most patients, particularly for those who are symptomatic from their disease. (See <a class="local">'Efficacy versus other treatments'</a> above.)</p><p></p><p class="bulletIndent2">Another option for patients with indolent disease after an initial response or a prolonged duration of stability with standard-dose somatostatin analog therapy is dose escalation of the somatostatin analog, but this is not a preferred strategy. (See <a class="local">'Control of tumor growth'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</li><li><a class="nounderline abstract_t">Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007; 21:1.</a></li><li><a class="nounderline abstract_t">Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083.</a></li><li><a class="nounderline abstract_t">Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.</a></li><li><a class="nounderline abstract_t">Riihimäki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016; 139:2679.</a></li><li><a class="nounderline abstract_t">Kaderli RM, Spanjol M, Kollár A, et al. Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis. JAMA Oncol 2019; 5:480.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Al-Toubah T, Cives M. Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors. JAMA Oncol 2019; 5:489.</a></li><li class="breakAll">Baudin E, Walter TA, Beron A, et al. First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with &lt;sup&gt;177&lt;/sup&gt;Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial (abstract). Annals of Oncology (2022) 33 (suppl_7): S410-S416. 10.1016/annonc/annonc1060. https://oncologypro.esmo.org/meeting-resources/esmo-congress/first-multicentric-randomized-phase-ii-trial-investigating-the-antitumor-efficacy-of-peptide-receptor-radionucleide-therapy-with-sup-177-sup-lute (Accessed on September 21, 2022).</li><li><a class="nounderline abstract_t">Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969.</a></li><li><a class="nounderline abstract_t">Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469.</a></li><li><a class="nounderline abstract_t">Kvols LK, Buck M, Moertel CG, et al. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 1987; 107:162.</a></li><li><a class="nounderline abstract_t">Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72:244.</a></li><li><a class="nounderline abstract_t">Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38:430.</a></li><li><a class="nounderline abstract_t">di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77:402.</a></li><li><a class="nounderline abstract_t">Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8:1041.</a></li><li><a class="nounderline abstract_t">Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93:1468.</a></li><li><a class="nounderline abstract_t">Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol 2013; 40:56.</a></li><li><a class="nounderline abstract_t">Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31:169.</a></li><li><a class="nounderline abstract_t">Panzuto F, Di Fonzo M, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 2006; 17:461.</a></li><li><a class="nounderline abstract_t">Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005; 52:1259.</a></li><li><a class="nounderline abstract_t">Frankton S, Bloom SR. Gastrointestinal endocrine tumours. Glucagonomas. Baillieres Clin Gastroenterol 1996; 10:697.</a></li><li><a class="nounderline abstract_t">Angeletti S, Corleto VD, Schillaci O, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998; 42:792.</a></li><li><a class="nounderline abstract_t">Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999; 18:13.</a></li><li><a class="nounderline abstract_t">Romeo S, Milione M, Gatti A, et al. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res 2006; 65:120.</a></li><li><a class="nounderline abstract_t">Okamoto M, Kishimoto M, Takahashi Y, et al. A case of malignant insulinoma: successful control of glycemic fluctuation by replacing octreotide injections with octreotide LAR injections. Endocr J 2013; 60:951.</a></li><li><a class="nounderline abstract_t">Hirshberg B, Cochran C, Skarulis MC, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer 2005; 104:264.</a></li><li><a class="nounderline abstract_t">Healy ML, Dawson SJ, Murray RM, et al. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma. Intern Med J 2007; 37:406.</a></li><li><a class="nounderline abstract_t">Stehouwer CD, Lems WF, Fischer HR, et al. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh) 1989; 121:34.</a></li><li><a class="nounderline abstract_t">Jawiarczyk A, Bolanowski M, Syrycka J, et al. Effective therapy of insulinoma by using long-acting somatostatin analogue. A case report and literature review. Exp Clin Endocrinol Diabetes 2012; 120:68.</a></li><li><a class="nounderline abstract_t">Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61:6.</a></li><li><a class="nounderline abstract_t">Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157.</a></li><li><a class="nounderline abstract_t">Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600.</a></li><li><a class="nounderline abstract_t">Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013; 42:557.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37:1014.</a></li><li><a class="nounderline abstract_t">Sidéris L, Dubé P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 2012; 17:747.</a></li><li><a class="nounderline abstract_t">Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16:2963.</a></li><li><a class="nounderline abstract_t">Verslype C, Carton S, Borbath I, et al. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. Acta Gastroenterol Belg 2009; 72:54.</a></li><li><a class="nounderline abstract_t">Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23:412.</a></li><li><a class="nounderline abstract_t">Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95:3276.</a></li><li><a class="nounderline abstract_t">Bianchi A, De Marinis L, Fusco A, et al. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel. J Endocrinol Invest 2011; 34:692.</a></li><li><a class="nounderline abstract_t">Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656.</a></li><li><a class="nounderline abstract_t">Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371:224.</a></li><li><a class="nounderline abstract_t">Michael M, Garcia-Carbonero R, Weber MM, et al. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist 2017; 22:272.</a></li><li><a class="nounderline abstract_t">Ter-Minassian M, Zhang S, Brooks NV, et al. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors. Oncologist 2017; 22:165.</a></li><li><a class="nounderline abstract_t">Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, et al. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. J Clin Oncol 2019; 37:2571.</a></li><li><a class="nounderline abstract_t">Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006; 17:1733.</a></li><li><a class="nounderline abstract_t">Kulke MH, Ruszniewski P, Van Cutsem E, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol 2017; 28:1309.</a></li><li><a class="nounderline abstract_t">Lamberti G, Faggiano A, Brighi N, et al. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Pavel M, Ćwikła JB, Lombard-Bohas C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer 2021; 157:403.</a></li><li><a class="nounderline abstract_t">Ayyagari R, Neary M, Li S, et al. Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors. Am Health Drug Benefits 2017; 10:408.</a></li><li><a class="nounderline abstract_t">Raj N, Cruz E, O'Shaughnessy S, et al. A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors. JCO Oncol Pract 2022; 18:e1533.</a></li><li><a class="nounderline abstract_t">Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.</a></li><li><a class="nounderline abstract_t">Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab 1995; 80:2768.</a></li><li><a class="nounderline abstract_t">Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12:1139.</a></li><li><a class="nounderline abstract_t">Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M &amp; B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846.</a></li><li><a class="nounderline abstract_t">Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23:759.</a></li><li><a class="nounderline abstract_t">Kunz PL, Graham NT, Catalano PJ, et al. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol 2023; 41:1359.</a></li><li><a class="nounderline abstract_t">Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24:401.</a></li><li><a class="nounderline abstract_t">Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012; 30:2963.</a></li><li><a class="nounderline abstract_t">Chan JA, Blaszkowsky L, Stuart K, et al. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer 2013; 119:3212.</a></li><li><a class="nounderline abstract_t">Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009; 15:338.</a></li><li><a class="nounderline abstract_t">Walter T, van Brakel B, Vercherat C, et al. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer 2015; 112:523.</a></li><li><a class="nounderline abstract_t">Murakami J, Lee YJ, Kokeguchi S, et al. Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol Rep 2007; 17:1461.</a></li><li><a class="nounderline abstract_t">Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326:519.</a></li><li><a class="nounderline abstract_t">Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762.</a></li><li><a class="nounderline abstract_t">Dilz LM, Denecke T, Steffen IG, et al. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 2015; 51:1253.</a></li><li><a class="nounderline abstract_t">Krug S, Boch M, Daniel H, et al. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. PLoS One 2015; 10:e0143822.</a></li><li><a class="nounderline abstract_t">Kunz PL, Balise RR, Fehrenbacher L, et al. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas 2016; 45:1394.</a></li><li><a class="nounderline abstract_t">Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007; 59:637.</a></li><li><a class="nounderline abstract_t">Oberg K, Casanovas O, Castaño JP, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res 2013; 19:2842.</a></li><li><a class="nounderline abstract_t">Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28:245.</a></li><li><a class="nounderline abstract_t">Zhang J, Francois R, Iyer R, et al. Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Inst 2013; 105:1005.</a></li><li><a class="nounderline abstract_t">Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26:3403.</a></li><li><a class="nounderline abstract_t">Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501.</a></li><li><a class="nounderline abstract_t">Faivre S, Niccoli P, Castellano D, et al. Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study. Ann Oncol 2016.</a></li><li><a class="nounderline abstract_t">de Mestier L, Walter T, Brixi H, et al. Sunitinib achieved fast and sustained control of VIPoma symptoms. Eur J Endocrinol 2015; 172:K1.</a></li><li><a class="nounderline abstract_t">Chen J, Wang C, Han J, et al. Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert Rev Anticancer Ther 2013; 13:737.</a></li><li><a class="nounderline abstract_t">Fountas A, Tigas S, Giotaki Z, et al. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment. Hormones (Athens) 2015; 14:438.</a></li><li><a class="nounderline abstract_t">Ohn JH, Kim YG, Lee SH, Jung HS. Transformation of nonfunctioning pancreatic neuroendocrine carcinoma cells into insulin producing cells after treatment with sunitinib. Endocrinol Metab (Seoul) 2013; 28:149.</a></li><li><a class="nounderline abstract_t">Raymond E, Hobday T, Castellano D, et al. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev 2011; 30 Suppl 1:19.</a></li><li><a class="nounderline abstract_t">Phan AT, Halperin DM, Chan JA, et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 2015; 16:695.</a></li><li><a class="nounderline abstract_t">Chan JA, Faris JE, Murphy JE, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol 2017; 35S: ASCO #228.</a></li><li><a class="nounderline abstract_t">Capdevila J, Fazio N, Lopez C, et al. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). J Clin Oncol 2021; 39:2304.</a></li><li><a class="nounderline abstract_t">Xu J, Shen L, Bai C, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21:1489.</a></li><li class="breakAll">HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors. Available at: https://www.hutch-med.com/suru-fda-nda/ (Accessed on June 01, 2022).</li><li><a class="nounderline abstract_t">Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28:69.</a></li><li><a class="nounderline abstract_t">Oh DY, Kim TW, Park YS, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer 2012; 118:6162.</a></li><li><a class="nounderline abstract_t">Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311.</a></li><li><a class="nounderline abstract_t">Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514.</a></li><li><a class="nounderline abstract_t">Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol 2016.</a></li><li><a class="nounderline abstract_t">van der Veldt AA, Kleijn SA. Advances in pancreatic neuroendocrine tumor treatment. N Engl J Med 2011; 364:1873; author reply 1873.</a></li><li><a class="nounderline abstract_t">Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009; 360:195.</a></li><li><a class="nounderline abstract_t">Fiebrich HB, Siemerink EJ, Brouwers AH, et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist 2011; 16:783.</a></li><li><a class="nounderline abstract_t">Ong GS, Henley DE, Hurley D, et al. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 2010; 162:1001.</a></li><li><a class="nounderline abstract_t">Bernard V, Lombard-Bohas C, Taquet MC, et al. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol 2013; 168:665.</a></li><li><a class="nounderline abstract_t">Kulke MH, Ou FS, Niedzwiecki D, et al. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocr Relat Cancer 2022; 29:335.</a></li><li><a class="nounderline abstract_t">Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95:1148.</a></li><li><a class="nounderline abstract_t">Hobday TJ, Qin R, Reidy-Lagunes D, et al. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol 2015; 33:1551.</a></li><li><a class="nounderline abstract_t">Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol 2022; 40:2818.</a></li><li><a class="nounderline abstract_t">McCarthy KE, Woltering EA, Espenan GD, et al. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 1998; 4:94.</a></li><li><a class="nounderline abstract_t">Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003; 44:1.</a></li><li><a class="nounderline abstract_t">Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32:123.</a></li><li><a class="nounderline abstract_t">McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237:718.</a></li><li><a class="nounderline abstract_t">Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43:610.</a></li><li><a class="nounderline abstract_t">Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003; 30:417.</a></li><li><a class="nounderline abstract_t">Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26:2124.</a></li><li><a class="nounderline abstract_t">Grozinsky-Glasberg S, Barak D, Fraenkel M, et al. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer 2011; 117:1377.</a></li><li><a class="nounderline abstract_t">Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145:276.</a></li><li><a class="nounderline abstract_t">Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012; 30:1100.</a></li><li><a class="nounderline abstract_t">Savelli G, Bertagna F, Franco F, et al. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide. Cancer 2012; 118:2915.</a></li><li><a class="nounderline abstract_t">Schillaci O, Corleto VD, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2:S186.</a></li><li><a class="nounderline abstract_t">Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26.</a></li><li><a class="nounderline abstract_t">Hörsch D, Ezziddin S, Haug A, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Eur J Cancer 2016; 58:41.</a></li><li><a class="nounderline abstract_t">Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29:2416.</a></li><li><a class="nounderline abstract_t">Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376:125.</a></li><li><a class="nounderline abstract_t">Brabander T, Van der Zwan WA, Teunissen JJ, et al. Long-term efficacy, survival and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 2017.</a></li><li><a class="nounderline abstract_t">Zhang J, Song Q, Cai L, et al. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2020; 146:1533.</a></li><li class="breakAll">FDA approval announcement for lutetium Lu 177 dotatate available online at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm (Accessed on January 29, 2018).</li><li class="breakAll">Lutetium Lu 177 dotatate injection. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf?et_cid=39972490&amp;et_rid=907466112&amp;linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2018%2f208700s000lbl.pdf (Accessed on January 29, 2018).</li><li><a class="nounderline abstract_t">Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017; 105:295.</a></li><li><a class="nounderline abstract_t">Kennedy KR, Turner JH, MacDonald WBG, et al. Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177 Lu-octreotate peptide radionuclide therapy. Cancer 2022; 128:2182.</a></li><li><a class="nounderline abstract_t">Hope TA, Abbott A, Colucci K, et al. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. J Nucl Med 2019; 60:937.</a></li><li><a class="nounderline abstract_t">Yordanova A, Wicharz MM, Mayer K, et al. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy. Clin Cancer Res 2018; 24:4672.</a></li><li><a class="nounderline abstract_t">Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31:844.</a></li><li><a class="nounderline abstract_t">Pandit-Taskar N, Modak S. Norepinephrine Transporter as a Target for Imaging and Therapy. J Nucl Med 2017; 58:39S.</a></li><li><a class="nounderline abstract_t">Nwosu AC, Jones L, Vora J, et al. Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 2008; 98:1053.</a></li><li><a class="nounderline abstract_t">Nguyen C, Faraggi M, Giraudet AL, et al. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 2004; 45:1660.</a></li><li><a class="nounderline abstract_t">Bongiovanni A, Maiorano BA, Azzali I, et al. Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel) 2021; 14.</a></li><li><a class="nounderline abstract_t">Yao JC, Strosberg J, Fazio N, et al. Activity &amp; safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, &amp; gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). Ann Oncol 2018; 29S: ESMO #viii467.</a></li><li><a class="nounderline abstract_t">Mehnert JM, Bergsland E, O'Neil BH, et al. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer 2020; 126:3021.</a></li><li><a class="nounderline abstract_t">Strosberg J, Mizuno N, Doi T, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res 2020; 26:2124.</a></li><li><a class="nounderline abstract_t">Halperin DM, Liu S, Dasari A, et al. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol 2022; 8:904.</a></li><li class="breakAll">Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC). Available at: https://clinicaltrials.gov/ct2/show/NCT02955069?term=02955069&amp;rank=1.</li><li class="breakAll">Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET). Available at: https://clinicaltrials.gov/ct2/show/NCT03043664?term=03043664&amp;rank=1.</li></ol></div><div id="topicVersionRevision">Topic 90664 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382262" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular genetics of neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322345" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664470" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27553864" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The epidemiology of metastases in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763436" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763444" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763444" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2168286" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703061" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2886085" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8389666" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675099" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625251" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402179" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732927" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Slow-release lanreotide treatment in endocrine gastrointestinal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23391113" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845567" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364959" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16001675" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : VIPomas: an update in diagnosis and management in a series of 11 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9113318" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gastrointestinal endocrine tumours. Glucagonomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9691916" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10374671" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16479142" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23665775" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A case of malignant insulinoma: successful control of glycemic fluctuation by replacing octreotide injections with octreotide LAR injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15937909" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Malignant insulinoma: spectrum of unusual clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17535385" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2545062" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22187292" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effective therapy of insulinoma by using long-acting somatostatin analogue. A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052063" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262022" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080605" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23591432" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Consensus guidelines for the management and treatment of neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23591432" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Consensus guidelines for the management and treatment of neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11334727" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22628056" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antitumor effects of somatostatin analogs in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20572298" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19402373" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955874" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095353" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067307" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704057" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25014687" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lanreotide in metastatic enteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28220021" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28179574" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31390276" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801334" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rationale for the use of somatostatin analogs as antitumor agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28327907" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31545377" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34597974" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29263774" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35724357" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532003" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7673422" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11583197" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3664486" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&amp;B 39831), a novel drug with potential as an alternative to dacarbazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27552969" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36260828" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421420" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22778320" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23733618" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118063" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25584486" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17487405" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1310159" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15570077" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25935542" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630134" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27171514" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16937105" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23459719" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917848" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23840053" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Current understanding of the molecular biology of pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18612155" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Activity of sunitinib in patients with advanced neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21306237" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27836885" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25305306" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Sunitinib achieved fast and sustained control of VIPoma symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23573816" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25553766" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24396670" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Transformation of nonfunctioning pancreatic neuroendocrine carcinoma cells into insulin producing cells after treatment with sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21308478" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25956795" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33945297" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966810" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966810" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933912" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22736481" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779618" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21306238" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Everolimus for advanced pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27621394" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21561355" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Advances in pancreatic neuroendocrine tumor treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129539" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Glycemic control in patients with insulinoma treated with everolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482586" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164213" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23392213" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35324465" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17031397" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25488966" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35649195" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9532411" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12515868" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11965607" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192318" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994522" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12634971" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445841" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21425137" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231629" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Identification of unknown primary tumors in patients with neuroendocrine liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22393097" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22020784" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604127" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644985" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26943056" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555692" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28076709" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28428192" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Long-term efficacy, survival and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32281025" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32281025" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32281025" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28402980" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35363879" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177 Lu-octreotate peptide radionuclide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31263080" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29950352" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32272208" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28864611" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Norepinephrine Transporter as a Target for Imaging and Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18283308" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15471830" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34067837" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Activity&amp;safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin,&amp;gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320048" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31980466" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35389428" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
